Balcázar-Hernández L, Rodríguez MA, Vargas-Ortega G, Mendoza-Zubieta V, González-Virla B

Language: Spanish
References: 10
Page: 72-78
PDF size: 393.02 Kb.

ABSTRACT

Tertiary hyperparathyroidism (THPT) is characterized by hypercalcemia and autonomous hyperparathyroidism in the context of persistent secondary hyperparathyroidism (SHPT). THPT is related with extraskeletal calcifications, calciphylaxis, fractures, bone pain, progressive loss of bone mineral density, nephrocalcinosis, lithiasis, kidney allograft dysfunction and rejection, neuropsychiatric alterations, cardiovascular disease, and high morbimortality. Subtotal parathyroidectomy is the gold standard for treatment, with high cure rates. We described a case of THPT as a manifestation of Bone Mineral Metabolism Disease after a successful kidney transplant, with an insidious evolution and severe bone damage, with an adequate response to subtotal parathyroidectomy. We evidenced that early diagnosis and treatment of THPT in kidney transplant recipients is essential to the diminution of comorbidities, the improvement of prognosis and the optimization of health resources.

REFERENCES

1. Schlosser K, Endres N, Celik I, Fendrich V, RothmundM, Fernández ED. Surgical treatment of tertiaryhyperparathyroidism: the choice of procedure matters!World J Surg. 2007;31(10):1947-53. doi: 10.1007/s00268-007-9187-z.

2. Tang JA, Friedman J, Hwang MS, Salapatas AM,Bonzelaar LB, Friedman M. Parathyroidectomy fortertiary hyperparathyroidism: A systematic review.Am J Otolaryngol. 2017;38(5):630-5. doi: 10.1016/j.amjoto.2017.06.009.

3. Shindo M, Lee JA, Lubitz CC, McCoy KL, Orloff LA,Tufano RP, et al. The Changing Landscape of Primary,Secondary, and Tertiary Hyperparathyroidism:Highlights from the American College of SurgeonsPanel, “What’s New for the Surgeon Caringfor Patients with Hyperparathyroidism”. J AmColl Surg. 2016;222(6):1240-50. doi: 10.1016/j.jamcollsurg.2016.02.024.

4. Sharma J, Weber C. Early versus late parathyroidectomyfor tertiary (posttransplant) hyperparathyroidism, p.209-16. En: Angelos P, Grogan RH. Difficult decisionsin endocrine surgery: an evidence-based approach.Springer, 2018. doi: 10.1007/978-3-319-92860-9.

5. Davies DR, Dent CE, Watson L. Tertiaryhyperparathyroidism. Br Med J. 1968;3(5615):395-9.doi: 10.1136/bmj.3.5615.395.

6. Moe S, Drüeke T, Cunningham J, Goodman W,Martin K, Olgaard K, et al. Definition, evaluation,and classification of renal osteodystrophy: a positionstatement from kidney disease: Improving GlobalOutcomes (KDIGO). Kidney Int. 2006;69(11):1945-53. doi: 10.1038/sj.ki.5000414.

7. Vangala C, Pan J, Cotton RT, Ramanathan V. Mineraland bone disorders after kidney transplantation. FrontMed. 2018;5:211. doi: 10.3389/fmed.2018.00211.

8. Thongprayoon C, Cheungpasitporn W. Persistenthyperparathyroidism after kidney transplantation;updates on the risk factors and its complications.J Parathyr Dis. 2018;6(1):26-8. doi: 10.15171/jpd.2018.09.

9. Balcázar-Hernández L, Vargas-Ortega G, González-Virla B, Cruz-López M, Rodríguez-Gómez R,Espinoza-Pérez R, et al. Biochemical characteristicsof bone mineral metabolism before and throughoutthe first year after kidney transplantation, persistenthyperparathyroidism, and risk factors in a latinpopulation. Int J Endocrinol. 2020;2020:6913506. doi: 10.1155/2020/6913506.

10. Dulfer RR, Franssen GJH, Hesselink DA, HoornEJ, van Eijck CHJ, van Ginhoven TM. Systematicreview of surgical and medical treatment for tertiaryhyperparathyroidism. Br J Surg. 2017;104(7):804-13.doi: 10.1002/bjs.1055.